Cybin Inc. (HELP): Major Partnership Boosts Veteran Care!

Introduction

Cybin Inc., doing business as Helus Pharma, is a clinical-stage biopharmaceutical company focused on novel psychedelic-based therapeutics for mental health (www.otcmarkets.com). In January 2026 the company rebranded to Helus Pharma and transferred its U.S. listing from the NYSE American (ticker CYBN) to the Nasdaq under the symbol “HELP” (www.otcmarkets.com). Helus’s lead drug candidates are proprietary “novel serotonergic agonists” (NSAs) targeting major depressive disorder (MDD) and anxiety disorders (www.otcmarkets.com). In late April 2026, Helus announced a major partnership with TARA Mind – a mental health organization – to support Phase 3 trial recruitment in veteran communities, aiming to expand veteran access to innovative treatments (www.taiwannews.com.tw). This collaboration aligns closely with a landmark U.S. Executive Order (issued April 18, 2026) on accelerating breakthrough mental health treatments for high-need groups like veterans (www.taiwannews.com.tw). Together, Helus and TARA Mind plan to boost veteran outreach for Helus’s Phase 3 MDD program (code-named PARADIGM – HLP003), bringing potentially life-changing therapy to a population suffering disproportionate rates of depression, PTSD, and suicide (www.taiwannews.com.tw) (www.taiwannews.com.tw). Management believes such partnerships will facilitate trial enrollment and raise mental health awareness in veteran communities, reinforcing Helus’s mission of “helping minds heal” and strengthening its alignment with federal initiatives to improve veteran care (www.taiwannews.com.tw).

Dividend Policy & Cash Flows

Like most development-stage biotech companies, Helus (formerly Cybin) does not pay any dividend and has no history of shareholder distributions. All available capital is reinvested into R&D and clinical programs. In fact, the company remains far from profitability – it generates virtually no revenue and continues to operate at a loss. For the quarter ended December 31, 2025 (Q3 FY2026), Helus reported a net loss of US$42.7 million, a sharp increase from a US$7.5 million loss in the same quarter a year prior (www.globenewswire.com). This widening loss reflects heavy spending on Phase 3 and Phase 2 trials (R&D and operations), with cash-based operating expenses of US$36.7 million in the quarter – nearly double the prior year’s quarter (www.globenewswire.com). Negative operating cash flow was about US$31.9 million for Q3, underscoring that Helus is consuming cash to fund its pipeline (www.globenewswire.com). Metrics like FFO or AFFO (funds from operations) are not applicable here, as Helus has no steady operating income – instead, its “funds from operations” are negative and financed by external capital. Consequently, dividend yield is 0%, and it will likely remain so until the company achieves sustainable profits (which hinges on successful drug approvals and commercialization). Investors in HELP stock today are thus focusing on capital gains potential rather than income, accepting that any payoff depends on clinical and regulatory success rather than near-term cash returns.

Balance Sheet Strength, Leverage & Debt Maturities

Despite ongoing losses, Helus entered 2026 with a strong balance sheet thanks to substantial recent financings. As of December 31, 2025, the company held approximately US$195 million in cash on hand (www.globenewswire.com). This cash buffer was bolstered by a $175 million registered equity offering completed in late 2025 (ir.helus.com). In that October 2025 deal, Helus issued ~22.28 million common shares (plus 4.6 million pre-funded warrants) at US$6.51 each, raising roughly US$175 million gross proceeds (ir.helus.com). The financing attracted both new and existing biotech-focused investors (including Venrock Healthcare), indicating market confidence in Helus’s prospects (ir.helus.com). In addition, the company set up an “at-the-market” program to sell up to $35 million in shares if needed (providing future fundraising flexibility).

Leverage: Notably, Helus carries minimal traditional debt – it has relied mostly on equity raises to fund operations. The primary debt on its books is a $50 million convertible debenture issued in June 2025 (ir.helus.com). This unsecured convertible note has a two-year term (maturing around mid-2027) and bears 5.5% annual interest, which the company pre-paid in full at closing (effectively eliminating ongoing interest cash outflow) (ir.helus.com). The conversion terms give the creditor (High Trail) the right to convert the note into equity at a formula-based price – roughly a 30% premium over Helus’s share price at issuance, subject to adjustment based on the share’s VWAP prior to conversion (ir.helus.com). Importantly, conversion is restricted to prevent the holder from owning more than 4.99% of outstanding shares at any time (ir.helus.com), meaning any conversion would likely occur in tranches. Beyond this convertible, Helus has no significant long-term loans or bank debt; its other liabilities are typical operating payables and lease obligations.

Maturity profile and coverage: With the convertible note not due until mid-2027, Helus faces no near-term debt maturities – a credit positive. Interest coverage in the classic sense is not meaningful here (given negative EBITDA), but liquidity is ample to meet all obligations for the foreseeable future. The 5.5% coupon on the $50 million note equates to ~$2.75 million per year, which has already been set aside (pre-paid) (ir.helus.com). In essence, Helus’s current net cash position (cash well above debt) means it can comfortably fund its R&D programs at least through its upcoming clinical milestones. Management has described the balance sheet as “strong” and sufficient to reach key data readouts (www.globenewswire.com) (www.globenewswire.com). That said, if the pipeline progresses toward regulatory approval, Helus may need additional capital for Phase 3 completion, FDA filing, and commercial launch preparations. The existing cash (nearly $200 million at year-end) and the shelf/ATM facility together position the company to avoid dilutive distress in the near term, but longer-term financing needs will depend on trial outcomes and partnering opportunities.

Valuation and Comparable Metrics

Helus Pharma’s stock (Nasdaq: HELP) currently trades around $5–6 per share, translating to a market capitalization near $270 million (www.gurufocus.com). At this price, Helus’s price-to-book ratio is ~1.0 (www.gurufocus.com) – meaning the market value is roughly equal to the company’s book value (which largely consists of cash and acquired intellectual property). With the firm still in a pre-revenue stage, traditional earnings multiples (P/E) are not applicable (Helus is in a loss-making phase) (www.gurufocus.com). Instead, investors often look at enterprise value relative to cash and pipeline value. Helus’s enterprise value (EV) is roughly $224 million (www.gurufocus.com) after adjusting for its cash and modest debt, implying that the market is valuing all of Helus’s drug pipeline and intellectual property at only ~$50 million above net cash. In other words, the current stock price suggests skepticism – the market is assigning a relatively low valuation to Helus’s pipeline potential, perhaps reflecting the high risk inherent in drug development.

Peer context: Among psychedelic-therapy developers, Helus is one of the better-capitalized but still modestly valued companies. For example, COMPASS Pathways (NASDAQ: CMPS), which is developing a psilocybin therapy for treatment-resistant depression, has a market cap of about $580 million as of Q1 2026 (www.tipranks.com) – roughly twice Helus’s size. Another peer, atai Life Sciences (ATAI), with a broader neuropsychiatry pipeline, has traded at similarly compressed valuations relative to cash. This suggests that Helus/HELP isn’t an outlier; the entire sector is trading at muted valuations after a wave of early enthusiasm in psychedelics gave way to more cautious, data-driven assessments. The flip side is that upside could be significant if Helus’s Phase 3 trial succeeds – current valuation leaves room for repricing if a clear path to FDA approval and commercialization emerges. Indeed, at least one Wall Street firm sees substantial upside: Jefferies initiated coverage on Helus in early 2026 with a “Buy” rating and a $22 price target, citing the company’s “science-driven psilocybin therapies” and leading position in novel depression treatments as key growth drivers (finance.yahoo.com). That target implies roughly 200%+ share price upside from current levels, underscoring how dramatically sentiment could shift on positive clinical news. However, investors should note that such bullish targets assume successful execution of trials and regulatory milestones that are still ahead. For now, Helus’s valuation image is that of a well-funded speculative play: it trades near cash value, which may limit downside, but the market remains in “wait-and-see” mode regarding the true value of Helus’s drug candidates.

Major Partnership to Boost Veteran Care (TARA Mind Collaboration)

A key recent development – and the inspiration for this report’s title – is Helus Pharma’s collaboration with TARA Mind to enhance mental health care for veterans. Announced on April 28, 2026, this partnership is strategically designed to support patient recruitment for Helus’s Phase 3 MDD trials (HLP003) by leveraging TARA Mind’s deep ties to veteran communities (www.taiwannews.com.tw) (www.taiwannews.com.tw). TARA Mind is a mental health organization experienced in connecting veterans with innovative treatment options. Through the partnership, TARA Mind will use its networks to identify and engage veterans who might benefit from (and be interested in) joining Helus’s clinical trial of HLP003 (www.taiwannews.com.tw) (www.taiwannews.com.tw). In addition to bolstering enrollment, the collaboration focuses on expanding awareness and access – educating veteran populations about emerging psychedelic therapies and how to participate in research that could address their unmet mental health needs (www.taiwannews.com.tw).

This initiative comes at a critical moment. On April 18, 2026, President Trump issued an Executive Order titled “Accelerating Medical Treatments for Serious Mental Illness.” This landmark Executive Order specifically calls for expanding clinical research participation and fast-tracking novel treatments for groups like veterans, who face disproportionately high rates of depression, PTSD, and suicide (www.taiwannews.com.tw). Helus’s partnership with TARA Mind is directly aligned with these national priorities. The company explicitly noted that the collaboration “directly aligns” with the Executive Order’s goals of advancing innovative care for veterans (www.taiwannews.com.tw). By increasing veteran engagement in its PARADIGM study (the Phase 3 program for HLP003), Helus not only helps fulfill a public health mandate but also potentially expedites its trial. Faster, more targeted recruitment means Helus can gather Phase 3 data more efficiently, bringing it closer to a potential first product approval. Interim CEO Eric So highlighted that “veterans face significant mental health challenges, and expanding awareness and access to clinical research opportunities is an important step toward improving outcomes”, praising TARA Mind’s experience with veteran communities (www.taiwannews.com.tw). He noted that these collaborations will support recruitment for HLP003 – which has FDA Breakthrough Therapy designation – while advancing broader goals from the recent Executive Order (www.taiwannews.com.tw).

In practical terms, the TARA Mind partnership should boost veteran care by connecting more veterans to cutting-edge trials, and it enhances Helus’s public profile as a veteran-friendly innovator. Although financial details of the partnership were not disclosed (it appears to be a cooperative agreement rather than a revenue-generating deal), the move is largely seen as a win-win. Veterans get improved access to a promising therapy in development, and Helus gains an expanded pool of motivated trial participants along with goodwill from policymakers and the veteran community. In a competitive landscape, such community and government engagement can be a differentiator. Helus has publicly expressed strong support for the federal push on psychedelic research (the company issued a statement supporting the Executive Order’s vision on April 20, 2026) and is positioning itself as a key player at the intersection of innovative neuropharma and public health policy (www.taiwannews.com.tw). This could pay dividends (strategically, if not financially) in the form of smoother regulatory interactions or even potential funding/grant opportunities aimed at veteran health. Overall, the TARA Mind collaboration is a positive development that underscores Helus’s commitment to its mission (“heal us” – as the name Helus implies) and could accelerate the path to proving HLP003’s efficacy in a real-world population that desperately needs new solutions.

Risks and Red Flags

While Helus Pharma shows promise, investors should remain cognizant of several risks and red flags:

– Clinical Trial Risk: Helus’s prospects hinge on the success of its Phase 3 HLP003 trial in depression (and to a lesser extent, the Phase 2 HLP004 trial in anxiety). There is no guarantee of efficacy or safety meeting FDA’s approval standards. Failure or even mediocre results in the Phase 3 APPROACH or EMBRACE studies would severely undermine the investment thesis. The Breakthrough Therapy status for HLP003 indicates FDA sees potential, but it does not assure approval (www.otcmarkets.com). Notably, on March 5, 2026 Helus reported statistically significant Phase 2 results for HLP004 (anxiety) (www.globenewswire.com), yet the stock dropped – reminding that positive data must clear a high bar to impress markets. The upcoming top-line readout for HLP003 (expected in Q4 2026) is the make-or-break catalyst (www.globenewswire.com); any delay or disappointment here is a major risk.

– Cash Burn and Financing: Helus is spending aggressively to run multiple trials, as evidenced by a $42M loss last quarter (www.globenewswire.com). Even with ~$195M in cash at year-end 2025, this runway is finite – likely around 1.5–2 years at the current burn rate. If trials take longer or additional studies are required, Helus may need to raise more capital well before reaching profitability. Future financings could dilute existing shareholders or add debt. The company has an unused capacity to issue up to $450M in additional convertible notes under its 2025 financing agreement (ir.helus.com), which, if tapped, could signal cash strain. While management has been proactive in fundraising (securing cash when stock prices were higher), the reliance on external capital is an ongoing risk.

– Dilution & Share Count Explosion: Helus’s equity base has expanded dramatically, which can dilute shareholder value. In 2024, Cybin/Helus executed a 1-for-38 reverse stock split, collapsing ~760 million pre-consolidation shares into ~20 million shares (www.nasdaq.com). However, subsequent financing nearly doubled the share count – by late 2025, ~22.3 million new shares (and additional warrants) were issued for the direct offering (ir.helus.com). Including warrant exercises and the Small Pharma acquisition shares, Helus likely has on the order of 45+ million shares (fully diluted) outstanding now. Moreover, the $50M convertible debenture can convert to equity – potentially adding millions more shares (the exact number depends on conversion price) (ir.helus.com). Such dilution can weigh on the stock price and reduce future upside for current holders. It’s a red flag that the Board even had to approve up to a 50:1 share consolidation in 2024 to maintain listing requirements (www.nasdaq.com), reflecting how much the float had ballooned. Investors should be prepared for further dilution if Helus raises additional equity capital, especially if done at lower prices.

– Executive Turnover: Frequent leadership changes raise concerns about execution. In February 2026 Helus appointed veteran pharma executive Michael Cola as CEO to lead the company into its next phase (commercial readiness) (www.globenewswire.com). Yet barely two months later, in April, the Board abruptly asked Cola to step down, reinstating co-founder Eric So as Interim CEO (www.globenewswire.com). Such rapid turnover at the top – Cola’s departure “effective immediately, at the request of the Board” (www.globenewswire.com) – is a potential red flag. It suggests possible strategic disagreements or performance issues. Stability in management will be crucial as Helus approaches pivotal trial readouts. Investors will want to see whether a new permanent CEO is brought in or if Eric So (Executive Chairman) continues to juggle the interim role. Any perception of internal instability could undermine investor and partner confidence.

– Regulatory and Market Adoption Risks: Helus is operating at the cutting edge of psychedelic medicine, an area where regulatory pathways are still evolving. Even if HLP003 succeeds in trials, the FDA approval process could encounter hurdles (e.g. needing additional safety data due to the psychoactive nature of the drug). Moreover, assuming approval, market adoption is not guaranteed. Psychedelic-assisted therapy represents a new treatment paradigm – it may require specialized clinics, trained therapists, and insurer buy-in. There could be stigma or logistical challenges in administering NSAs (which likely involve supervised therapy sessions). For the veteran population in particular, Helus might need to coordinate with the VA (Veterans Affairs health system) to integrate its treatment. These uncertainties mean the commercial ramp could be slower or costlier than traditional pill-based medications, posing a risk to future revenue projections.

– Competition: The neuropsychiatric treatment space is becoming crowded. Helus’s deuterated psilocybin analog (HLP003) will likely compete with Compass Pathways’ psilocybin (if approved) and possibly other rapid-acting antidepressants (like Spravato or even MDMA-assisted therapy for PTSD). Larger pharmaceutical companies could also enter the fray through acquisitions or their own trials if psychedelics gain traction. Helus, as a small company, could find itself competing against far better-resourced players. While its patent portfolio is large (350+ filed, 100+ granted patents) (www.otcmarkets.com) (www.otcmarkets.com), the competitive landscape and IP will need monitoring. Any advantages Helus claims (e.g. a shorter trip duration or better pharmacokinetics for HLP003) will need to be clearly demonstrated to differentiate from competitors.

– Red Tape and Ethical Concerns: As a final note, working with psychedelics often involves navigating controlled substance regulations. Helus will need DEA clearance for manufacturing and trial use of its drug, and later scheduling decisions could affect deployment. Although the policy environment is warming – exemplified by the Executive Order and Breakthrough designations – any regulatory pushback or delays outside the FDA (e.g. Congress or state-level restrictions) could pose risks. Additionally, because Helus is targeting vulnerable populations (e.g. veterans with serious mental health issues), any adverse events or misuse could attract negative publicity or political scrutiny, a risk not present for more conventional drugs.

In sum, Helus faces the typical binary outcomes of a late-stage biotech: tremendous upside if it delivers on its science, but significant downside if things go awry. The company has mitigated some risks with a strong cash position and strategic focus, but investors should remain cautious and keep these risk factors in mind.

Open Questions & Outlook

Looking ahead, several open questions remain that will determine Cybin/Helus’s ultimate success or failure:

– Will HLP003’s Phase 3 trials meet their endpoints? The top-line APPROACH trial data is expected by Q4 2026 (www.globenewswire.com). A clear antidepressant benefit (with acceptable safety) is critical. How robust will the effect size be, and will it hold up across both pivotal studies? These results will likely make or break the stock.

– What is the path to FDA approval and commercialization? If Phase 3 is positive, Helus could file for FDA approval in 2027. How smoothly will that process go, given the novel nature of psychedelic therapy? Additionally, can Helus commercialize HLP003 on its own – building a sales and patient-support infrastructure for a psychedelic treatment – or will it need to partner with a larger pharma company for marketing and distribution? Management has started hiring commercial team members (e.g. medical affairs, people operations) (www.globenewswire.com) (www.globenewswire.com), but launching a new therapy is a huge endeavor for a small firm. A partnership or buyout is a real possibility if the data are strong.

– Is Helus’s cash sufficient to reach profitability? With ~$195M in cash and an ongoing ~$30–40M quarterly burn (www.globenewswire.com) (www.globenewswire.com), Helus likely has around 4–6 quarters of funding before needing more capital. If HLP003 is approved, initial revenues might start flowing by late 2027 or 2028 – but can Helus bridge the gap without a dilutive raise or additional debt? The company’s financing strategy (including whether it draws on that additional $450M convertible facility) bears watching. Ideally, positive trial outcomes would boost the stock price, enabling more favorable financing if needed. Conversely, any trial hiccup could tighten the cash vise.

– How will the veteran-focused strategy play out? The partnership with TARA Mind and alignment with the Executive Order clearly position Helus as an ally in veteran mental health. Will this yield tangible benefits beyond trial recruitment – for instance, could Helus secure Department of Veterans Affairs collaborations or grants? And post-approval, might the VA become an early adopter/customer of HLP003 for veterans? A lot depends on how well Helus can convert its goodwill and trial data into formal relationships with veteran healthcare systems.

– What about Helus’s broader pipeline? While HLP003 is the flagship, Helus also has HLP004 (anxiety) and acquired assets like SPL026 (from the Small Pharma acquisition) which showed positive Phase 2a results for depression (www.globenewswire.com). How will these candidates be advanced? Will Helus prioritize getting HLP003 to market first, or run parallel programs? The management bandwidth and cash constraints may limit how much can be done at once. Investors may want clarity on whether non-core programs might be out-licensed or spun off to conserve resources for the main effort.

– Can Helus maintain strategic focus and leadership stability? The sudden CEO shuffle in April 2026 raises the question of long-term leadership. Will the company bring in a new permanent CEO with commercialization expertise, or is a potential merger/acquisition on the table (where a larger company takes over)? The answer may influence how aggressively Helus invests in its own sales infrastructure versus courting a buyout. Additionally, can the current team execute a Phase 3 program and NDA filing on schedule? Consistency in execution will be key in the upcoming 12–18 months.

In conclusion, Cybin Inc. (Helus Pharma) has positioned itself at the forefront of next-generation mental health treatments, with a particular emphasis on serving veterans through recent partnerships. The HELP ticker feels apt – the company’s goal is to help heal minds, and if its therapies succeed, it could transform care for depression and anxiety. However, the road ahead is not without obstacles. Investors should stay tuned for clinical updates (especially the big MDD trial readout) and watch how management navigates the complex journey from promising data to an approved drug on the market. The pieces are in place – solid funding, government support, and compelling science – but only execution will determine if Helus can truly deliver a breakthrough “help” to patients and reward to shareholders.

Sources: Helus/Cybin investor disclosures and SEC filings; press releases and GlobeNewswire announcements; financial data from GuruFocus; and relevant news coverage as cited above. The inline citations (in brackets) reference the specific source and line number for verification of key facts and figures.

For informational purposes only; not investment advice.